Gsk (GSK) Income from Continuing Operations (2009 - 2026)

Gsk (GSK) has 18 years of Income from Continuing Operations data on file, last reported at $3.5 billion in Q3 2026.

• For the quarter ending Q3 2026, Income from Continuing Operations changed N/A year-over-year to $3.5 billion; the trailing twelve-month figure through Sep 2026 stood at $13.8 billion (changed N/A YoY), and the FY2025 full-year result was $11.3 billion, up 121.3% from the prior year.
• Income from Continuing Operations was $3.5 billion for Q3 2026 at Gsk, up from $208.0 million in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of $6.8 billion in Q4 2025 to a low of $81.9 million in Q3 2024.
• A 5-year average of $3.0 billion and a median of $2.8 billion in 2025 frame the typical range for Income from Continuing Operations.
• Across the five-year window, Income from Continuing Operations slumped 96.84% in 2024 and jumped 4462.94% in 2025, its largest moves.
• Gsk's Income from Continuing Operations stood at $4.3 billion in 2022, then jumped by 33.09% to $5.8 billion in 2023, then decreased by 24.92% to $4.3 billion in 2024, then jumped by 56.77% to $6.8 billion in 2025, then plunged by 48.53% to $3.5 billion in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were $3.5 billion in Q3 2026, $208.0 million in Q2 2026, and $3.3 billion in Q1 2026.